Advent Life Sciences is a venture capital firm specializing in early and mid-stage investments in life sciences companies across the UK, Europe, and the USA. The firm focuses on new drug discovery—including small molecules, biologics, and new modalities—as well as medical technology, enabling technologies, and vaccines. With a hands-on approach, Advent collaborates closely with management teams to transform breakthrough science into approved medicines and medical products.
Is Advent Life Sciences the right investor for your startup? Browse their investment focus, stage preferences, and geographic scope to see how well they align with your fundraising goals. Your full match score with Advent Life Sciences, along with a list of other relevant VCs, is available on Hopohopo.io.
Investment role
Lead and follow
Stages
Seed, Series A
First ticket size
£1,000,000 - £5,000,000
When approaching Advent Life Sciences, founders should highlight the scientific rigor and translational potential of their technology, demonstrating a clear path from discovery to clinical impact. Emphasize strong data, differentiated mechanisms, and a credible plan for regulatory and commercial milestones. Advent values teams with deep domain expertise and a collaborative mindset, so showcasing a track record of execution and openness to partnership will resonate. Articulate how your innovation addresses unmet medical needs and can scale within global healthcare markets.
Stop wasting weeks searching for the right investors. Upload your deck and get matched with investors who actually fit your startup — so you can focus on building, not chasing.